New England Journal of Medicine Publishes Data from Phase 3 Studies Demonstrating Oveporexton (ORZEYFUL) Improved the Full Range of Narcolepsy Type 1 Symptoms and Quality of Life
Go back to New England Journal of Medicine Publishes Data from Phase 3 Studies Demonstrating Oveporexton (ORZEYFUL) Improved the Full Range of Narcolepsy Type 1 Symptoms and Quality of Life| (NYSE: TAK) | Delayed: 20.36 +0.43 (2.16%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $19.93 | 52 Week High | $0.55 | |||
| Open | $20.18 | 52 Week Low | $0.55 | |||
| Day High | $20.39 | P/E | N/A | |||
| Day Low | $20.08 | EPS | $-0.20 | |||
| Volume | 3,461,936 | |||||



